Multiple Myeloma Clinical Trial
Official title:
A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies
Verified date | July 2017 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
Status | Completed |
Enrollment | 175 |
Est. completion date | December 3, 2009 |
Est. primary completion date | December 3, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: - Adult patients (=18 years old) with advanced hematological malignancies who relapsed after or are refractory to standard therapy, or for which no standard therapy existed; or, were considered inappropriate candidates for standard therapy - World Health Organization (WHO) performance status = 2 - Patients who met protocol-specified hematologic and non-hematologic laboratory values - Patients with adequate liver and renal function Exclusion criteria: - Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid - Peripheral neuropathy = CTCAE grade 2 - Unresolved diarrhea = CTCAE grade 2 - Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study, including impaired heart function or clinically significant heart disease, and impaired gastrointestinal function or disease that significantly altered aborption of LBH589 - Female patients who were pregnant or breast feeding - Patients who were unwilling to use an effective method of birth control - Patients who took medications specified by the protocol as prohibited for administration in combination with LBH589 - Patients with another primary malignancy that required active intervention or were clinically significant |
Country | Name | City | State |
---|---|---|---|
Australia | Novartis Investigative Site | Parkville | Victoria |
Australia | Novartis Investigative Site | Prahran | Victoria |
Germany | Novartis Investigative Site | Frankfurt/M | |
Germany | Novartis Investigative Site | Mainz | |
United States | Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia | Augusta | Georgia |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | MD Anderson Cancer Center/University of Texas | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Australia, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants DLT in Arm 1 in Dose Escalation Phase | Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for consecutive dosing schedule (MWF weekly). A 3-parameter version of a Bayesian logistic regression model with overdose control (Babb, Rogatko, and Zacks 1998) was used during the dose escalation phase for dose level selection and determination of the MTD. | Cycle 1 (28-day treatment cycle) | |
Primary | Number of Participants DLT in Arm 2 in Dose Escalation Phase | Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for intermittent dosing schedule (MWF weekly). A 3-parameter version of a Bayesian logistic regression model with overdose control (Babb, Rogatko, and Zacks 1998) was used during the dose escalation phase for dose level selection and determination of the MTD. |
Cycle 1 (28-day treamtent cycle) | |
Secondary | Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML) | Response as per investigator assessment for patients include complete response, progressive disease/failure, stable disease. | 3.5 years | |
Secondary | Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML) in Expansion Phase | Stage 2 did not open for enrollment. | 1.2 years | |
Secondary | Response as Per Investigator Assessment for Patients With Hodgkin's Lymphoma (HD) | Response as per investigator assessment for patients include complete response, partial remission, stable disease, progressive disease (PD)/failure. | 3.5 years | |
Secondary | Response as Per Investigator Assessment for Patients With Myelodysplastic Syndromes (MDS) | Response as per investigator assessment for patients include complete response, stable disease, progressive disease/failure, partial remission. | 3.5 years | |
Secondary | Maximum Plasma Concentration of Panobinostat After the First Dose in Arms 1 and 2 | Day 1 | ||
Secondary | Half Life of Panobinostat After the First Dose in Arms 1 and 2 | Day 1 | ||
Secondary | Maximum Plasma Concentration of Panobinostat After Multiple Doses in Arm 1 on Day 15 | From day 15 by dose with schedule: MWF every week | Day 15 | |
Secondary | Half Life of Panobinostat After Multiple Doses in Arm 1 on Day 15 | Day 15 | ||
Secondary | Geometric Mean Ratio (GMR) Comparing Treatment Days in Arm 1 | MWF Every week schedule n = number of subjects with non-missing values. | Day 15/day 1 | |
Secondary | Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group X | Reporting the number of patients with a reading at the timepoint in the dose group. | Days 1, 5, 8, 10, 15 | |
Secondary | Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group Y | Days 5, 8, end of study (up to 3.5 years) | ||
Secondary | Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group X | Days 5, 8, 10, 12, 15, End of study, Unscheduled (up to 3.5 years) | ||
Secondary | Percentage of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group Y | Days 5, 8, 10, 12, 15, End of study (up to 3.5 years) | ||
Secondary | Highest Percent Change in Fetal Hemoglobin From Baseline in Arm 1 (MWF Every Week) | All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (= 7 days post last dose (preferably = 4 days [96 hours])) | Post dose to pre-dose (up to 3.5 years) | |
Secondary | Highest Percent Change of Fetal Hemoglobin From Baseline in Arm 2 (MWF Every Other Week) | All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (= 7 days post last dose (preferably = 4 days [96 hours])) | Post dose to pre-dose (up to 3.5 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |